Emergent BioSolutions | EBS - Current Liabilities


Emergent BioSolutions reported $651.3M in Current Liabilities for its fiscal quarter ending in December of 2023.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Akebia Therapeutics USD 173.88M 10.95M Mar/2026
ALKERMES USD 662.09M 62.59M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Amarin USD 164.2M 15.45M Jun/2026
ANI Pharmaceuticals USD 239.51M 38.6M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Exelixis USD 370.98M 34.67M Mar/2026
Glaxosmithkline GBP 22.43B 6.39B Mar/2026
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
Ironwood Pharmaceuticals USD 236.31M 5.91M Mar/2026
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
Lonza CHF 3.57B 421M Dec/2025
Merck USD 26.94B 1.38B Mar/2026
Moderna USD 2.53B 139M Jun/2026
Myriad Genetics USD 130.7M 500K Jun/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Pacira USD 122.01M 13.22M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
United Therapeutics USD 607.8M 8.7M Jun/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025